News Tag: Corporate Information

The subscription price for exercise of warrants of series TO13B in iZafe Group AB has been set at SEK 0.20 per share of series B, and the exercise period begins tomorrow February 23

In November 2022 iZafe Group AB ("iZafe" or the "Company") acquired Pilloxa AB and, in connection with the acquisition, carried out a directed issue of units consisting of shares of series B and warrants of series TO13B. To compensate existing shareholders for the dilution from the directed issue of units, and with the purpose of capitalizing iZafe in a favorable way, the Company issued warrants of series TO13B free of charge to all shareholders. A total of 118,556,833 warrants of series TO13B were issued. Each warrant gives the right to subscribe for one (1) new share of series B in the Company. The subscription price has been set to SEK 0.20 per share of series B. The exercise period for warrants of series TO13B runs from February 23, 2023, up to and including March 8, 2023.

Each warrant gives the right to subscribe for one (1) new share of series B in the Company. The subscription price for the warrants of series TO13B shall correspond to 70 percent of the
volume-weighted average price of the Company's share of series B on Nasdaq First North Growth Market during the measurement period from and including February 9, 2023, up to and including February 22, 2023. However, not lower than the quota value for the Company's share, corresponding to SEK 0.20, and not higher than SEK 0.30 per share. The volume-weighted average price of the Company's share of series B during the measurement period amounted to approximately SEK 0.21. Thus, the subscription price is determined to SEK 0.20. The exercise period for warrants of series TO13B runs from February 23, 2023, up to and including March 8, 2023. Complete terms and conditions for the warrants of series TO13B are available on the Company's website, www.izafegroup.com.

Summarized terms for the warrants of series TO13B:

Exercise period: February 23, 2023 – March 8, 2023.

Exercise price: SEK 0.20 per share of series B.

Issue size: 118,556,833 warrants of series TO13B, which entitles to subscription of 118,556,833 shares of series B. If all the warrants are exercised, the Company will receive approximately SEK 23.7 million before issuing costs.

Last day for trading warrants of series TO13B: March 6, 2023.

Share capital and dilution: If all warrants are exercised the share capital will increase with SEK 23,711,366.60, from SEK 30,756,066.00 to SEK 54,467,432.60. If all warrants are exercised the number of shares will increase with 118,556,833 shares of series B, in total the number of shares in the Company will increase from 153,780,330 shares to 272,337,163 shares (600,000 shares of series A and 271,737,163 shares of series B). The dilution at full exercise of all warrants amounts to approximately 43.53 percent of the number of shares and 42.69 percent of the votes in the Company.
Note that the warrants of series TO13B that are not exercised at the latest March 8, 2023, or sold at the latest March 6, 2023, will expire without value. For the warrants not to lose their value, the holder must actively subscribe for new shares or sell the warrants. Please note that some trustees may close their registration earlier than 8 March 2023.

Advisors
Mangold Fondkommission AB is the financial advisor and Eversheds Sutherland Advokatbyrå AB is the legal advisor to the Company in connection with the exercise of the warrants of series TO13B.

Contacts

Anders Segerström, Chief Executive Officer 
E-mail:
Phone number: +46 70-875 14 12

iZafe Group AB (publ.)
Södra Fiskartorpsvägen 20
114 33 Stockholm

E-mail: 
www.izafe.se/investor-relations/

About Us

iZafe Group is a Swedish Life-Science company that develops and markets medical and digital security solutions to create safer drug handling at home. The company’s digital medication dispenser Dosell reduces the risk of incorrect medication, increases security for family and relatives and relieves public care personnel. The products form a holistic concept that facilitates patient medication and gives those who are treated at home better conditions for a happy and safe life. Customers today consist of public and private care providers in Sweden, the Nordic countries and globally. iZafe Group sells primarily through well-established partners who already have long and deep customer relationships with the priority customer groups. The head office is located in Stockholm.

The company is listed on the NASDAQ First North Premier Growth Market. FNCA Sweden AB is the company's Certified Adviser. Phone: +46 (0) 8 528 00 399. E-mail: . Further information is available at www.izafe.se/investor-relations/.

Attachments

The subscription price for exercise of warrants of series TO13B in iZafe Group AB has been set at SEK 0.20 per share of series B, and the exercise period begins tomorrow February 23

The subscription price for exercise of warrants of series TO13B in iZafe Group AB has been set at SEK 0.20 per share of series B, and the exercise period begins tomorrow February 23

iZafe has been granted a new patent for safer medication handling at home

iZafe Group AB (publ.) announces that the Swedish Patent and Registration Office (PRV) intends to grant another patent application of iZafe Group. The patent, titled "System and procedure for medication delivery arranged to adjust a pre-defined and pre-packaged medication dose based on a patient-specific parameter," applies to the company's technology for medical and digital security solutions to create safer medication management in the home.

"This patent gives us additional protection in Sweden for medication handling at home. After the acquisition of Pilloxa, we are able to offer solutions for safe medication for the entire patient journey, which in practice means the following steps:
• Pill jars or other loose medicine in syringes, tablets or liquid form. Where, with the help of our app, we remind, show statistics and can send alarms.
• Sorting in "dosett" where we offer a smart connected version that, with the help of our app, helps with sorting, reminders, alarms and statistics.
• Medication in sachets where, with the help of Dosell, we automate the entire process in the medication.
With this patent, we can also create a unique solution for safer medication handling in the home and addressing a significent and increasing demand" says Anders Segerström, CEO of iZafe Group.

Contacts

Anders Segerström, Chief Executive Officer 
E-mail:
Phone number: +46 70-875 14 12

iZafe Group AB (publ.)
Södra Fiskartorpsvägen 20
114 33 Stockholm

E-mail: 
www.izafe.se/investor-relations/

About Us

iZafe Group is a Swedish Life-Science company that develops and markets medical and digital security solutions to create safer drug handling at home. The company’s digital medication dispenser Dosell reduces the risk of incorrect medication, increases security for family and relatives and relieves public care personnel. The products form a holistic concept that facilitates patient medication and gives those who are treated at home better conditions for a happy and safe life. Customers today consist of public and private care providers in Sweden, the Nordic countries and globally. iZafe Group sells primarily through well-established partners who already have long and deep customer relationships with the priority customer groups. The head office is located in Stockholm.

The company is listed on the NASDAQ First North Premier Growth Market. FNCA Sweden AB is the company's Certified Adviser. Phone: +46 (0) 8 528 00 399. E-mail: . Further information is available at www.izafe.se/investor-relations/.

Attachments

iZafe has been granted a new patent for safer medication handling at home

iZafe has been granted a new patent for safer medication handling at home

The medication robot Dosell is being implemented in two new municipalities

iZafe Group (publ.) hereby announces that the partner Careium Sweden AB is now starting the implementation of Dosell in two more municipalities in Sweden.

The municipalities, which together have approximately 13,500 residents aged 65 and over, initially start with 10 Dosells and then gradually increase the number.

Lack of adherence to medication is a major societal problem, which requires large resources to deal with. Dosell solves medication management in an efficient way and thus frees up the staff's time for care.

"We look forward to continuing the implementation of Dosell in more municipalities in the future and thereby working for greater independence for care recipients," says Martin Puumalainen Director Nordics and International for Careium AB

About Careium
Careium is one of the leading players in welfare technology in Europe and around 400,000 people use their services. The vast majority of these are connected to one of the company's four alarm centers in Sweden, Norway and Great Britain. The alarm centers receive more than 25,000 alarms a day. Read more at careium.com

About Dosell
The medicinal robot Dosell is a Swedish-made digital aid for safer medication at home and for people living in nursing homes. Dosell is integrated into welfare platforms and is sold as one of several integrated digital aids via partners.
In a Swedish report, it is estimated that 3,000 Swedes die annually from drug-related injuries and that 6–16 percent of hospital admissions are drug-related. The costs for drug-related injuries that can be avoided are estimated at SEK 5.6–24.6 billion per year.
Dosell notifies the patient when it's time to take the medicine, and if the medicine is not taken despite the reminders, Dosell alerts healthcare professionals or relatives who can quickly prevent an injury and improve compliance, thus minimizing drug-related injuries.
Read more at www.dosell.com

Contacts

Anders Segerström, Chief Executive Officer 
E-mail:
Phone number: +46 70-875 14 12

iZafe Group AB (publ.)
Södra Fiskartorpsvägen 20
114 33 Stockholm

E-mail: 
www.izafe.se/investor-relations/

About Us

iZafe Group is a Swedish Life-Science company that develops and markets medical and digital security solutions to create safer drug handling at home. The company’s digital medication dispenser Dosell reduces the risk of incorrect medication, increases security for family and relatives and relieves public care personnel. The products form a holistic concept that facilitates patient medication and gives those who are treated at home better conditions for a happy and safe life. Customers today consist of public and private care providers in Sweden, the Nordic countries and globally. iZafe Group sells primarily through well-established partners who already have long and deep customer relationships with the priority customer groups. The head office is located in Stockholm.

The company is listed on the NASDAQ First North Premier Growth Market. FNCA Sweden AB is the company's Certified Adviser. Phone: +46 (0) 8 528 00 399. E-mail: . Further information is available at www.izafe.se/investor-relations/.

Attachments

The medication robot Dosell is being implemented in two new municipalities

The medication robot Dosell is being implemented in two new municipalities

iZafe resolves on the record date for allotment of, and first day of trading in, warrants of series TO13B

As announced by press release on November 28, 2022, the Board of Directors of iZafe Group AB (publ) ("iZafe" or the "Company") has decided to distribute warrants free of charge to shareholders in the Company. The record date for allotment of warrants of series TO13B has been set to December 23, 2022. The exercise period to subscribe for new shares with the support of warrants of series TO13B will be from and including February 23, 2023, to and including March 8, 2023. The first day of trading in the warrants of series TO13B on Nasdaq First North Growth Market will be on December 28, 2022.

As announced by press release on November 28, 2022, iZafe has completed a directed issue of shares and warrants of series TO13B (the “Directed Issue”). In order to give existing shareholders in the Company the opportunity to compensate for the dilution the Directed Issue entails, the Board of Directors of iZafe has also decided to issue warrants of series TO13B (same series as in the Directed Issue) to the Company, which then are allotted free of charge to the shareholders in the Company.

The record date to receive warrants of series TO13B has been set to December 23, 2022. Therefore, the last day of trading in the Company’s share including the right to receive warrants is December 21, 2022, and the first day of trading in the Company’s share excluding the right to receive warrants is December 22, 2022.

The Company’s existing shareholders will receive one (1) free warrant of series TO13B for every two (2) shares held in the Company on the record date.

Terms and information regarding warrants of series TO13B

Each warrant of series TO13B gives the right to subscribe for one (1) new share in the Company during the period from and including February 23, 2023, to and including March 8, 2023. The subscription price for shares of series B supported by warrants of series TO13B amounts to 70 percent of the volume weighted average price of the Company's share on the Nasdaq First North Premier Growth Market during the period from and including February 9, 2023, to and including February 22, 2023, however, the share's minimum quota value (currently SEK 0.20) and a maximum of SEK 0.30.

41,666,668 warrants of series TO13B are allotted to the investors in the Directed Issue and 76,890,165 warrants of series TO13B are allotted to the shareholders of the Company. In the event of full utilization of warrants of series TO13B, the Company can receive an additional maximum of approximately SEK 35.6 million, depending on the subscription price. If all of the Company's 118,556,833 issued warrants of series TO13B are exercised, the number of shares in the Company will increase by 118,556,833 shares, from 153,780,330 shares to 272,337,163 shares, and the share capital will increase by SEK 23,711,366.60, from SEK 30,756,066.00 to SEK 54,467,432.60. Which entails a total dilution for the Company's existing shareholders of approximately 43.53 percent of the numbers of shares and approximately 42.69 percent of the votes.

Advisors
Mangold Fondkommission AB is the finacial advisor to iZafe in connection with the warrants of series TO13B.

Contacts

Anders Segerström, Chief Executive Officer 
E-mail:
Phone number: +46 70-875 14 12

iZafe Group AB (publ.)
Södra Fiskartorpsvägen 20
114 33 Stockholm

E-mail: 
www.izafe.se/investor-relations/

About Us

iZafe Group is a Swedish Life-Science company that develops and markets medical and digital security solutions to create safer drug handling at home. The company’s digital medication dispenser Dosell reduces the risk of incorrect medication, increases security for family and relatives and relieves public care personnel. The products form a holistic concept that facilitates patient medication and gives those who are treated at home better conditions for a happy and safe life. Customers today consist of public and private care providers in Sweden, the Nordic countries and globally. iZafe Group sells primarily through well-established partners who already have long and deep customer relationships with the priority customer groups. The head office is located in Stockholm.

The company is listed on the NASDAQ First North Premier Growth Market. FNCA Sweden AB is the company's Certified Adviser. Phone: +46 (0) 8 528 00 399. E-mail: . Further information is available at www.izafe.se/investor-relations/.

Attachments

iZafe resolves on the record date for allotment of, and first day of trading in, warrants of series TO13B

iZafe resolves on the record date for allotment of, and first day of trading in, warrants of series TO13B

Change of Certified Adviser (CA) to Mangold Fondkommission AB

iZafe Group AB (publ) hereby announces that the company has entered into an agreement with Mangold regarding the service as Certified Adviser.

Mangold will take over as Certified Adviser (CA) on 1 April 2023. Until then, FNCA will continue to act as Certified Adviser for the company.

Contacts

Anders Segerström, Chief Executive Officer 
E-mail:
Phone number: +46 70-875 14 12

iZafe Group AB (publ.)
Södra Fiskartorpsvägen 20
114 33 Stockholm

E-mail: 
www.izafe.se/investor-relations/

About Us

iZafe Group is a Swedish Life-Science company that develops and markets medical and digital security solutions to create safer drug handling at home. The company’s digital medication dispenser Dosell reduces the risk of incorrect medication, increases security for family and relatives and relieves public care personnel. The products form a holistic concept that facilitates patient medication and gives those who are treated at home better conditions for a happy and safe life. Customers today consist of public and private care providers in Sweden, the Nordic countries and globally. iZafe Group sells primarily through well-established partners who already have long and deep customer relationships with the priority customer groups. The head office is located in Stockholm.

The company is listed on the NASDAQ First North Premier Growth Market. FNCA Sweden AB is the company's Certified Adviser. Phone: +46 (0) 8 528 00 399. E-mail: . Further information is available at www.izafe.se/investor-relations/.

Attachments

Change of Certified Adviser (CA) to Mangold Fondkommission AB

Change of Certified Adviser (CA) to Mangold Fondkommission AB

iZafe begins collaboration with ApoEx for enhanced patient safety

iZafe Group (publ.) hereby announces that it has signed a cooperation agreement with ApoEx AB, which is a supplier of pharmacy services, systems and dosage bags to privately and publicly run healthcare providers.

“iZafe and the medicine robot Dosell are the only products on the market that can handle the dose bags that we deliver to our customers in outpatient and inpatient care. We are happy to develop the collaboration with iZafe, which is completely in line with our business concept of offering technical solutions to customers in public and private healthcare”, says John Patrick Berlips, licensed physician and founder of ApoEx.

ApoEx supplies dose bags to 3,500 patients and hospitals in several of the country's regions. In Stockholm, the company produces the sachets that, among others, Aleris uses in its healthcare deliveries.

“ApoEx offers smart comprehensive solutions of goods and services for both private and public healthcare and is therefore the right partner for us. As iZafe is currently in an expansive phase, our strategic partnerships are absolutely crucial for us. With these collaborations, we can more effectively develop successful solutions together”, says Anders Segerström, CEO of iZafe.

About ApoEx
ApoEx was founded in 2010 with the aim of simplifying and improving care. We have developed most solutions in close dialogue with our customers and the business is characterized by customer-driven innovation and the attitude that nothing is impossible. Over the years, thousands of healthcare companies in the private and public sector have chosen ApoEx as their strategic partner for the supply of medicines and consumables.

Contacts

Anders Segerström, Chief Executive Officer 
E-mail:
Phone number: +46 70-875 14 12

iZafe Group AB (publ.)
Södra Fiskartorpsvägen 20
114 33 Stockholm

E-mail: 
www.izafe.se/investor-relations/

About Us

iZafe Group is a Swedish Life-Science company that develops and markets medical and digital security solutions to create safer drug handling at home. The company’s digital medication dispenser Dosell reduces the risk of incorrect medication, increases security for family and relatives and relieves public care personnel. The products form a holistic concept that facilitates patient medication and gives those who are treated at home better conditions for a happy and safe life. Customers today consist of public and private care providers in Sweden, the Nordic countries and globally. iZafe Group sells primarily through well-established partners who already have long and deep customer relationships with the priority customer groups. The head office is located in Stockholm.

The company is listed on the NASDAQ First North Premier Growth Market. FNCA Sweden AB is the company's Certified Adviser. Phone: +46 (0) 8 528 00 399. E-mail: . Further information is available at www.izafe.se/investor-relations/.

Attachments

iZafe begins collaboration with ApoEx for enhanced patient safety

iZafe begins collaboration with ApoEx for enhanced patient safety

iZafe Group signs an agreement with Medcam AB, an international supplier of medical technology

iZafe Group (publ.) hereby announces that it has signed a cooperation agreement with Medcam AB, which sells medical technology products to healthcare in the Nordics and Europe. In the first place, the focus will be on the Dutch market, but the company has the potential for several countries in the near term.

"We have a high demand for products that enable a more digital healthcare where medication and compliance are an important factor. The pharmaceutical robot Dosell is a perfect complement to this, ensuring compliance in a safe way, while being integrated to enable more proactive and digital care.
The Dutch market has very great potential and we are starting this collaboration, as the demand from our customers is high for pharmaceutical robots", says Robert Camara, CEO of Medcam.

"The Dutch market has long been a goal for us to enter, as it is the country that has come the furthest in Europe regarding medication in sachets. We are now ready to start more collaborations that enable us to expand to several markets and look forward to starting work with Medcam and their customers", says Anders Segerström, CEO of iZafe Group.

About Medcam
MedCam AB markets and sells medical technology products and focuses on high quality products from stable suppliers. The company's business concept is to supply the Nordic and European market with high-quality products at good prices with high service.
The company's suppliers are located all over the world, i.a. USA, France, Germany and China. Medcam constantly strives to be able to satisfy customers' needs and demand and continuously searches the market, in order to be able to offer better and innovative products now and for the future.
For more information, read more at www.medcam.se

About Dosell
The medicinal robot Dosell is a Swedish-made digital aid for safer medication at home and for people living in nursing homes. Dosell is integrated into welfare platforms and is sold as one of several integrated digital aids via partners.
In a Swedish report, it is estimated that 3,000 Swedes die annually from drug-related injuries and that 6–16 percent of hospital admissions are drug-related. The costs for drug-related injuries that can be avoided are estimated at SEK 5.6–24.6 billion per year.
Dosell notifies the patient when it's time to take the medicine, and if the medicine is not taken despite the reminders, Dosell alerts healthcare professionals or relatives who can quickly prevent an injury and improve compliance, thus minimizing drug-related injuries.
Read more at www.dosell.se

Contacts

Anders Segerström, Chief Executive Officer 
E-mail:
Phone number: +46 70-875 14 12

iZafe Group AB (publ.)
Södra Fiskartorpsvägen 20
114 33 Stockholm

E-mail: 
www.izafe.se/investor-relations/

About Us

iZafe Group is a Swedish Life-Science company that develops and markets medical and digital security solutions to create safer drug handling at home. The company’s digital medication dispenser Dosell reduces the risk of incorrect medication, increases security for family and relatives and relieves public care personnel. The products form a holistic concept that facilitates patient medication and gives those who are treated at home better conditions for a happy and safe life. Customers today consist of public and private care providers in Sweden, the Nordic countries and globally. iZafe Group sells primarily through well-established partners who already have long and deep customer relationships with the priority customer groups. The head office is located in Stockholm.

The company is listed on the NASDAQ First North Premier Growth Market. FNCA Sweden AB is the company's Certified Adviser. Phone: +46 (0) 8 528 00 399. E-mail: . Further information is available at www.izafe.se/investor-relations/.

Attachments

iZafe Group signs an agreement with Medcam AB, an international supplier of medical technology

iZafe Group signs an agreement with Medcam AB, an international supplier of medical technology

Warrants of series TO10B were subscribed to approximately 34.1 percent and iZafe Group AB receives approximately SEK 3.14 million

iZafe Group AB (publ.) (”iZafe” or the ”Company”) today announces the outcome of the exercise of warrants of series TO10B, which were issued during the fourth quarter of 2021. In total, 12,072,688 warrants of series TO10B were exercised, corresponding to approximately 34.1 percent of the total number of outstanding warrants of series TO10B, for subscription of 12,072,688 B-shares at a subscription price of SEK 0.26 per B-share. iZafe will receive approximately SEK 3.14 million before issuing costs through the exercise of the warrants of series TO10B.

Background
The subscription period for exercise of the warrants of series TO10B took place from September 27, 2022, up to and including October 11, 2022. The subscription price per B-share for exercising the warrants of series TO10B was set to SEK 0.26.

In total, 12,072,688 warrants of series TO10B were exercised for subscription of 12,072,688 B-shares, meaning that approximately 34.1 percent of all outstanding warrants of series TO10B were exercised for subscription of B-shares.

Exercised warrants have been replaced with interim shares (IA), pending registration with the Swedish Companies Registration Office. The interim shares are expected to be converted to B-shares within approximately three (3) weeks.

Number of shares, share capital and dilution
Through the exercise of the warrants of series TO10B, the number of shares in iZafe increases by 12,072,688 B-shares, from 70,874,308 shares (consisting of 600,000 A-shares och 70,274,308
B-shares) to a total of 82,946,996 shares. The share capital will increase by SEK 2,414,537.60 from SEK 14,174,861.60 to SEK 16,589,399.20.

For existing shareholders who did not exercise any warrants of series TO10B, the dilution amounts to approximately 14.6 percent of the number of shares and approximately 13.7 percent of the number of votes in the Company.

Advisors
Mangold Fondkommission AB is the financial advisor and Eversheds Sutherland Advokatbyrå AB is the legal advisor to the Company in connection with the exercise of the warrants of series TO10B.

Contacts

Anders Segerström, Chief Executive Officer 
E-mail:
Phone number: +46 70-875 14 12

iZafe Group AB (publ.)
Södra Fiskartorpsvägen 20
114 33 Stockholm

E-mail: 
www.izafe.se/investor-relations/

About Us

iZafe Group is a Swedish Life-Science company that develops and markets medical and digital security solutions to create safer drug handling at home. The company’s digital medication dispenser Dosell reduces the risk of incorrect medication, increases security for family and relatives and relieves public care personnel. The products form a holistic concept that facilitates patient medication and gives those who are treated at home better conditions for a happy and safe life. Customers today consist of public and private care providers in Sweden, the Nordic countries and globally. iZafe Group sells primarily through well-established partners who already have long and deep customer relationships with the priority customer groups. The head office is located in Stockholm.

The company is listed on the NASDAQ First North Premier Growth Market. FNCA Sweden AB is the company's Certified Adviser. Phone: +46 (0) 8 528 00 399. E-mail: . Further information is available at www.izafe.se/investor-relations/.

This information is information that iZafe Group is obliged to make public pursuant to the EU Market Abuse Regulation. The information was submitted for publication, through the agency of the contact persons set out above, at 2022-10-13 07:20 CEST.

Attachments

Warrants of series TO10B were subscribed to approximately 34.1 percent and iZafe Group AB receives approximately SEK 3.14 million

Warrants of series TO10B were subscribed to approximately 34.1 percent and iZafe Group AB receives approximately SEK 3.14 million

iZafe and Aleris start pilot projects for safer medication

iZafe Group AB (publ.) announces today that it is starting a pilot project with Aleris. The aim of the project is to produce decision-making material for a potential introduction of the pharmaceutical robot Dosell in Aleris for the patient group advanced healthcare in the home (ASIH

In October will 30 patients in the advanced home healthcare, in Region Stockholm, will receive for the first time a robot that will help them take their medicine. The aim is to reduce the risk of medication mistreatment, underdosing and overdosing or mixing up medication. In some cases, the risk of abuse can also be reduced.

— Pharmaceutical robots mean major positive changes for patient safety. If the patient does not take their medication, an alarm is sent to our nurses, says Maria Frick, registered pharmacist at Aleri's local health care.

Aleris has investigated the possibility of introducing so-called pharmaceutical robots within advanced home healthcare in the Stockholm Region. A total of 30 Dosell pharmaceutical robots from iZafe have been purchased. During October, the pharmaceutical robot will be introduced to the first patient treated in advanced healthcare at home (ASIH).

— We see great opportunities with pharmaceutical robots in specialist healthcare. Innovation and technology that can help our patients to greater independence while increasing or maintaining patient safety is important to us, says Maria Frick.

It is the first time a pharmaceutical robot has been integrated into advanced home healthcare.

— We are extremely proud to continue to contribute to helping several patient groups and making everyday life easier with our unique pharmaceutical robot. We look forward to starting the implementation of Dosell at Aleris. After three months, an evaluation is carried out to see how many pharmaceutical robots the business wishes to bring in, says Anders Segerström, CEO iZafe Group.

For certain patient groups, the robot is an important aid. Last year, the poison information center received a number of calls about patients who, due to wrong dosage or mix-up, had taken the wrong medicine. 61 percent of them were recommended to seek medical care. Many serious overdoses are found in the group.

— A medication robot tells when a patient should take their medication, at the same time medication for future administration occasions is inaccessible, says Maria Frick.

Another advantage of pharmaceutical robots is increased efficiency and the opportunity to spend resources on more value-creating activities.

Not all patients in specialist healthcare are suitable for a medication robot, an assessment is always made and confirmed with the doctor that the patient can manage their medication with and that it is a suitable solution for this particular individual.

This is how a pharmaceutical robot works in specialist healthcare
The medication robot, no bigger than a shoebox, is placed in the patient's home. The robot is loaded with the patient's prescribed medication packaged in sachets. The medication robot reads the time for the next medication intake and at the correct date and time a dose bag is fed forward and thus becomes available to the patient. To remind you that it is time to take medicine, the robot signals with light and sound.

If for some reason the patient does not remove his dose bag from the robot, the patient's nurse will receive an alarm about this and then contact the patient, either through a phone call or a visit.

For further information contact:
Kenan Harbas, press manager Aleris, +46 707 834 203
Anders Segerström, CEO iZafe Group, +46 70-875 14 12

About Aleris
Aleri's vision is to lead the way to tomorrow's health and care. Through innovative solutions, we create opportunities for a better and healthier life while contributing to increased accessibility and social benefit. Aleris is a Scandinavian healthcare provider with two million patient visits a year and provides specialist healthcare at over 130 locations in Sweden, Norway and Denmark.

About Dosell
The pharmaceutical robot Dosell is a Swedish-made digital aid for safer medication at home and for residents in nursing homes. Dosell is integrated into welfare platforms and sold as one of several integrated digital aids via partners. Dosell notifies the patient when it is time to take the medication, and if the medication is not taken despite the reminders, Dosell alerts healthcare staff or relatives who can quickly prevent an injury from occurring as well as improve compliance and thereby minimize medication-related injuries.

Contacts

Anders Segerström, Chief Executive Officer 
E-mail:
Phone number: +46 70-875 14 12

iZafe Group AB (publ.)
Södra Fiskartorpsvägen 20
114 33 Stockholm

E-mail: 
www.izafe.se/investor-relations/

About Us

iZafe Group is a Swedish Life-Science company that develops and markets medical and digital security solutions to create safer drug handling at home. The company’s digital medication dispenser Dosell reduces the risk of incorrect medication, increases security for family and relatives and relieves public care personnel. The products form a holistic concept that facilitates patient medication and gives those who are treated at home better conditions for a happy and safe life. Customers today consist of public and private care providers in Sweden, the Nordic countries and globally. iZafe Group sells primarily through well-established partners who already have long and deep customer relationships with the priority customer groups. The head office is located in Stockholm.

The company is listed on the NASDAQ First North Premier Growth Market. FNCA Sweden AB is the company's Certified Adviser. Phone: +46 (0) 8 528 00 399. E-mail: . Further information is available at www.izafe.se/investor-relations/.

Attachments

iZafe and Aleris start pilot projects for safer medication

iZafe and Aleris start pilot projects for safer medication

The Italian sachet market is starting to gain momentum

iZafe Group (publ.) hereby announces that the partner Remedio has sold its concept to 12 pharmacies which in a short time have 2,000 active customers who receive their medicines in sachets.

"Getting the medicine in sachets is completely new to the Italian market and our concept is based on local pharmacies purchasing a machine to enable their customers to have the medicine delivered in sachets. In a short time, we have now succeeded in installing machines for packing medicine into sachets in 12 pharmacies. These pharmacies have in turn gotten 2,000 of their customers to start getting their medicines delivered in sachets. Of these, about 95% are users in nursing homes. We currently have a rate of 2 new pharmacies a month installing a machine.
 
We will now start actively selling Dosell to these customers, but we will also start tests to introduce corportare version of Dosell, as most of our customers patients are now in nursing homes." says Alessandro Iadecola, CEO Remedio S.R.L.
 
 
"Getting several pharmacies to start packaging the medicines in sachets is absolutely crucial for Dosell, which is based on loading the medicine robot with these sachets. It will be exciting to follow the development on the Italian market, where it is now finally starting to gain momentum. Extra happy that so many nursing homes are starting to show interest in getting the medicine in sachets, as there are 3,000 nursing homes with over 300,000 beds in Italy." says Anders Segerström, CEO of iZafe Group AB.

Contacts

Anders Segerström, Chief Executive Officer 
E-mail:
Phone number: +46 70-875 14 12

iZafe Group AB (publ.)
Södra Fiskartorpsvägen 20
114 33 Stockholm

E-mail: 
www.izafe.se/investor-relations/

About Us

iZafe Group is a Swedish Life-Science company that develops and markets medical and digital security solutions to create safer drug handling at home. The company’s digital medication dispenser Dosell reduces the risk of incorrect medication, increases security for family and relatives and relieves public care personnel. The products form a holistic concept that facilitates patient medication and gives those who are treated at home better conditions for a happy and safe life. Customers today consist of public and private care providers in Sweden, the Nordic countries and globally. iZafe Group sells primarily through well-established partners who already have long and deep customer relationships with the priority customer groups. The head office is located in Stockholm.

The company is listed on the NASDAQ First North Premier Growth Market. FNCA Sweden AB is the company's Certified Adviser. Phone: +46 (0) 8 528 00 399. E-mail: . Further information is available at www.izafe.se/investor-relations/.

Attachments

The Italian sachet market is starting to gain momentum

The Italian sachet market is starting to gain momentum
Webbdesign av Comlog Webbyrå Stockholm